Clearstead Advisors’s BridgeBio Pharma BBIO Stock Holding History

Clearstead Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94K	Buy	26 +19	+271%	+$1.33K	﹤0.01%	2491
2026 Q1	$520	Hold	7	–	–	﹤0.01%	2115
2025 Q4	$536	Sell	7 -181	-96%	-$11.9K	﹤0.01%	2302
2025 Q3	$9.77K	Sell	188 -1	-0.5%	-$49	﹤0.01%	1939
2025 Q2	$8.16K	Buy	+189	New	+$6.87K	﹤0.01%	1957
2024 Q4	–	Sell	-90	Closed	-$2.29K	–	2104
2024 Q3	$2.29K	Hold	90	–	–	﹤0.01%	1821
2024 Q2	$2.28K	Buy	+90	New	+$2.46K	﹤0.01%	1799
2022 Q2	–	Sell	-3,979	Closed	-$40K	–	1280
2022 Q1	$40K	Buy	+3,979	New	+$40.8K	﹤0.01%	721

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Clearstead Advisors's BBIO Position: Q2 2026 in Review

Clearstead Advisors increased its BridgeBio Pharma (BBIO) stake by 271% in Q2 2026, buying an estimated $1.33K and bringing the position to 26 shares worth $1.94K. The position accounts for ﹤0.01% of the portfolio, ranked #2491.

Clearstead Advisors first reported a position in BBIO in Q1 2022 and has held it in 8 quarters since. The position peaked at $40K in Q1 2022. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Clearstead Advisors held 26 shares of BridgeBio Pharma worth $1.94K as of Q2 2026.
Clearstead Advisors bought 19 BridgeBio Pharma shares in Q2 2026, an estimated $1.33K.
BridgeBio Pharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2491 holding.
Clearstead Advisors first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 8 quarters since.
Clearstead Advisors's BridgeBio Pharma position peaked at $40K in Q1 2022.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.